Lai Yeng Lee

Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme.

Paclitaxel loaded biodegradable poly-(DL-lactic-co-glycolic) acid (PLGA) foams with microporous matrix were fabricated by a novel pressure quenching approach to provide a sustained paclitaxel release. The foams with micropores provided increased surface area to volume ratio and were also implantable for post-surgical chemotherapy applications. The two formulations 5% (w/w) paclitaxel loaded PLGA 85:15 foam (F1) and 10% (w/w) paclitaxel loaded PLGA 50:50 foam (F2), were evaluated in vitro and in vivo. Both the foams were found to provide a paclitaxel release beyond a month in vitro with a near zero-order kinetics and with minimum burst release. Furthermore, apoptosis of C6 glioma cells in vitro demonstrated the benefits of sustained paclitaxel release by the foams in comparison to acute Taxol exposure. Both the foams exhibited continuous paclitaxel release in an in vivo (subcutaneous) environment up to a month which correlated well with the in vitro release profiles. Bio-distribution results in the rat brain showed paclitaxel penetration at therapeutic levels up to 3mm into the tissue from the site of foam implantation. Hence these foams could be employed as potential implants for post-surgical chemotherapy against malignant glioma.

Characterization of porous poly(D,L-lactic-co-glycolic acid) sponges fabricated by supercritical CO2 gas-foaming method as a scaffold for three-dimensional growth of Hep3B cells

This study presents the application of the porous poly(D,L‐lactic‐co‐glycolic acid) (PLGA) sponges fabricated from an organic solvent free supercritical gas foaming technique. Two formulations of PLGA sponges with different co‐polymer compositions (85:15 and 50:50) were fabricated as novel scaffolds to guide human hepatoma cell line, Hep3B cell growth in vitro. The PLGA sponges showed desirable biodegradability and exhibited uniform pore size distribution with moderate interconnectivity. It was observed in this study that cells cultured on PLGA sponges showed lower proliferation rate as compared to the control during 14 days of culture as measured by using total DNA and methylthiazol tetrazolium (MTT) assays. However, the cells cultured on the sponges tended to aggregate to form cell islets which were able to express better hepatic functions. The enzyme‐linked immunosorbent assay (ELISA) results showed that the cell‐sponge constructs secreted 1.5–3.0 times more albumin than the control when normalized to cellular content. In a similar fashion, its detoxification ability was also predominantly higher than that of the control as indicated by the ethoxyresorufin‐O‐deethylase (EROD) results. By comparing the cells growing on the two formulations of PLGA sponges, it was found that the PLGA 85:15 sponge exhibited better conductive and desirable environment for hep3B cells as justified by better cell infiltration, higher proliferation and hepatic function than the PLGA 50:50 sponge. Biotechnol. Bioeng. 2008;100: 998–1009.

PLGA/chitosan composites from a combination of spray drying and supercritical fluid foaming techniques: new carriers for DNA delivery.

The use of poly(D, L-lactic-co-glycolic acid) for DNA delivery application is limited by its negative surface charge and acidic degradation products. The motivation of the present work was to study the effects of chitosan incorporation into PLGA foams on DNA delivery. PLGA/chitosan composite foams loaded with luciferase plasmid were fabricated by a combination of spray drying and supercritical CO2 foaming techniques. The resultant composite foams showed good morphology and chitosan was found to be poorly crystallized in the PLGA matrixes. The composite foams exhibited a sustained release of DNA (5-9 weeks) with decreasing release rate upon increasing content of chitosan. With this encapsulation technique, it was also observed that the integrity of plasmid was well maintained. Moreover, cell culture results proved that the bioactivity of plasmid released from all foams was well maintained and the incorporation of chitosan in foams helps increase cell adhesion and maintain high cell viability. Therefore, it can be concluded that PLGA/chitosan composite foams fabricated by combining spray drying and supercritical CO2 foaming are promising in DNA delivery applications.

Lysine-based peptide-functionalized PLGA foams for controlled DNA delivery

Due to its hydrophobicity and negatively charged surfaces, PLGA-based scaffolds have encountered problems in controlled-release and tissue engineering applications. The effects of charge modification of PLGA micro-porous foams on DNA delivery and DNA transfection are investigated herein. Tailor-designed l-lysine peptides (K4 and K20) were employed to modify the surface charge of PLGA foams using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide cross linkers and the effects of charge modification of PLGA were examined in three main aspects: DNA adsorption, DNA release properties and DNA transfection. Successful conjugation of peptide and DNA adsorption were verified by X-ray photoelectron spectroscopy. A plasmid encoding bone morphogenetic protein-2 (BMP2) was used throughout the current study and the results indicate that adsorption capacity and release behavior of DNA were highly dependent on the charge properties of the foam surfaces. The release rates of DNA from the K4- and K20-functionalized foams are more sustainable as compared to the blank foam. As a result, the sustained release of DNA from modified foams led to negligible cytotoxicity and sustained expression of DNA which is favorable for DNA delivery and tissue engineering application. Furthermore, the ease of fabrication and modification of PLGA foams makes it a promising DNA delivery device.

Diphenylalanine peptide nanotubes self-assembled on functionalized metal surfaces for potential application in drug-eluting stent

This study focuses on the potential of diphenylalanine self-assembled peptide nanotubes (FF Nts) for delivery of flufenamic acid (FA) from metal implants. Self-assembly of FF Nts was studied in solution and on surfaces of glass, silicone and gold substrates. FA was loaded inside the shell of FF Nts and subsequently FF/FA Nts were attached to gold surfaces. The substrate were characterized by Field Emission Scanning Electron Microscopy (FESEM), fluorescence microscopy, confocal microscopy, and UV-vis spectroscopy. Release of FA from FF Nts were investigated by immersing coated metal substrates in phosphate-buffered saline for 12 days. Self-assembly of FF in water and solvent resulted in formation of nanotubes, which efficiently loaded 98% of FA with concentration of 20 µg/mL. FESEM images confirmed successful attachment of FF/FA Nts to functionalized gold substrates. In vitro release studies indicated using FF Nts has prolonged the release rate of FA for several days. Biocompatibility studied confirmed more than 50% of the cells were alive in concentration of 250-1000 µg/mL of FF Nts thus suggesting the potential of peptide based self-assemble nanostructures as an alternate system for polymer coating in drugs eluting stents.

Drug delivery systems for programmed and on-demand release

&NA; With the advancement in medical science and understanding the importance of biodistribution and pharmacokinetics of therapeutic agents, modern drug delivery research strives to utilize novel materials and fabrication technologies for the preparation of robust drug delivery systems to combat acute and chronic diseases. Compared to traditional drug carriers, which could only control the release of the agents in a monotonic manner, the new drug carriers are able to provide a precise control over the release time and the quantity of drug introduced into the patients body. To achieve this goal, scientists have introduced “programmed” and “on‐demand” approaches. The former provides delivery systems with a sophisticated architecture to precisely tune the release rate for a definite time period, while the latter includes systems directly controlled by an operator/practitioner, perhaps with a remote device triggering/affecting the implanted or injected drug carrier. Ideally, such devices can determine flexible release pattern and intensify the efficacy of a therapy via controlling time, duration, dosage, and location of drug release in a predictable, repeatable, and reliable manner. This review sheds light on the past and current techniques available for fabricating and remotely controlling drug delivery systems and addresses the application of new technologies (e.g. 3D printing) in this field.